

L'AIOM LAZIO DISCUTE SAN ANTONIO

1 febbraio 2012

Aula A (Aula Urbani) - piano terra Policlinico Sant' Andrea

Introduzione all'incontro Teresa Gamucci

**Saluto del Preside della Facoltà di Medicina e Chirurgia Università "Sapienza" - Roma
Prof. Vincenzo Ziparo**

14.00-14.15 Nuove indicazioni di pratica clinica da San Antonio **PAOLO MARCHETTI**

Moderatori Ida Pavese Paolo Marchetti

14.15-14.30

Macrophages as Novel Targets for Therapy in Breast Cancer

MARCELLA MOTTOLESE

14.30-14.40 Discussione

14.40-15.00

Update of International Breast Cancer Study Group trial
23-01 to compare axillary dissection versus no axillary dissection
in patients with clinically node negative breast cancer and
micrometastases in the sentinel node

Changes in the Management of the axilla in breast cancer

TERESA DI PALMA

15.00-15.15 Discussione

Moderatori: Clara Natoli – Franco Angelini

15.15-15.35

Neoadjuvant chemotherapy adapted by interim response
improves overall survival of primary breast cancer patients –
results of the GeparTrio Trial

Neoadjuvant pertuzumab and trastuzumab concurrent or
sequential with an anthracycline-containing or concurrent with an
anthracycline-free standard regimen: A randomized phase II study
(TRYPHAENA)

PAOLA PAPALDO

15.35-15.55

Everolimus for postmenopausal women with advanced
breast cancer: updated results of the BOLERO-2 phase II trial

Neoadjuvant chemotherapy of paclitaxel with or without
Rad001: Results of the non-responder part of the GEPARQUINTO
study (GBG 44)

PATRIZIA VICI

15.55-16.20 Discussione

Moderatori: Cecilia Nisticò - Daniele Santini

16.20-16.50

ABCSG-12: 7-Year Results Show Durable Improvement in DFS With Adjuvant Zoledronic Acid in Premenopausal Women With Endocrine-Responsive Early Breast Cancer

ZO-FAST: 5-Year Data Show Combining Adjuvant Zoledronic Acid With Letrozole Continues to Improve BMD and DFS in Postmenopausal Women With Early Breast Cancer

NSABP B-34: Adjuvant Therapy Plus Oral Clodronate Does Not Prolong DFS vs Adjuvant Therapy Alone in Women With Early Breast Cancer

ANDREA MICHELOTTI

16.50-17.10 Discussione

Moderatori: Teresa Gamucci - Giuseppe Tonini

17.10-17.25

A phase II, randomized, double-blind, placebo-controlled registration trial to evaluate the efficacy and safety of pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in patients with previously untreated HER2-positive metastatic breast cancer (CLEOPATRA)

EMANUELA MAGNOLFI

17.25-17.45

First results of AVEREL, a randomized phase II trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

A phase 2, randomized, open-label, study of neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer

ALESSANDRA FABI

17.45-18.00 Discussione

Moderatori: Germano Zampa - Mariella Mauri

18.00-18.30

Menopause-specific and health-related qualities of life among post-menopausal women taking exemestane for prevention of breast cancer: Results from the NCIC CTG MAP.3 placebo-controlled randomized controlled trial

Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole

A Phase II randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for

postmenopausal women with metastatic breast cancer: SWOG
S0226
GIUSEPPE NASO

18.30-18.45 Discussione